Buscar noticias, acciones... Mercados Mercados Divisas Calculadora Divisas Materias Primas Carteras consenso ...

The most common adverse event (≥10% in any treatment group) was headache, which occurred in 24 percent of patients in the VX-150 group and 12 percent of patients in the placebo group.

For comparison, Lyrica, a standard of care drug which is ... including studies which used previous molecules Vertex developed such as VX-150) that validated the mechanism of action.

Biotech giant Vertex Pharmaceuticals, which made its name in the rare cystic fibrosis, is widening its aperture in hopes of treating a much more common ailment: chronic pain. The company is wading ...

Vertex Pharmaceuticals Incorporated VRTX announced positive results from a phase II study evaluating its NaV1.8 inhibitor VX-150 in patients suffering from pain caused by small fiber neuropathy.

Vertex Pharmaceuticals Incorporated Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis CAMBRIDGE, Mass.

Mar 27, 2008 -- Vertex Pharmaceuticals Incorporated ... the G551D mutation in CFTR who received either VX-770 or placebo in addition to standard therapies for 14 days as part of a blinded ...

Vertex Standard LMR, Inc.'s VX-260 analog series of radios provide a greater array of features for the maximum value. The series is targeted for customers across a broad range of areas including ...

Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of this year. In addition, the FDA has granted VX-548 Breakthrough Therapy Designation for the ...